AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01927302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: No treatment will be administered.
Study NCT00766441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: tablet, 100mg, once daily, 4 weeks
Study NCT01383200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: 0.5% Tetracaine Left eye / 2% Lidocaine Right eye
Study NCT04592380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1: Clevidipine (double-blinded)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
Study NCT04592380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stage 1: Placebo (double-blinded)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
Study NCT04592380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2: Clevidipine (open-label)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
Study NCT04592380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stage 2: Standard of Care (open-label)
Description: Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
Study NCT03556683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline
Description: 4 mL of 3% hypertonic saline
Study NCT03556683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline
Description: 4 mL of 7% hypertonic saline
Study NCT03254017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral surgical implantation of DBS system to Habeluna
Description: The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
Study NCT03254017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Period
Description: The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
Study NCT02940054 — intervention group
Intervention type: OTHER
Intervention: Red-flags questionnaire
Description: A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
Study NCT01358500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intravenous infusion using STANPUMP
Study NCT00766441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: sulphonylurea, variable, od or bd, during ramadan
Study NCT03593941 — intervention group
Intervention type: OTHER
Intervention: Standard Diet
Description: Participants will consume the standard diet provided in care home
Study NCT02431520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-collection
Description: Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
Study NCT02431520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecologist collection
Description: Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
Study NCT02075970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alpha
Description: Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1.
Study NCT02075970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epoetin Alpha
Description: Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1.
Study NCT02922712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NISE
Description: Nise 200mg Max per day in 2 divided doses
Study NCT00653705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt drink with probiotic bacteria BB12
Description: Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
Study NCT00653705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vanilla flavored dairy drink. One bottle a day for 16 weeks.
Study NCT03791424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administering premedication with sedative drug to relieve anxiety
Study NCT03791424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administering premedication with sedative drug to relieve anxiety
Study NCT01872754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Remifentanil
Description: 1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
Study NCT01872754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2: Propofol
Description: 2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
Study NCT04130425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hely & Weber MTC Fracture Brace
Description: Prefabricated muenster orthosis
Study NCT04130425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic orthosis
Description: Muenster orthosis fabricated out of thermoplastics and secured with Velcro
Study NCT04130425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta cast orthosis
Description: Muenster orthosis fabricated out of Delta Cast and secured with Velcro
Study NCT02075970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotinylated Red Blood Cells
Description: Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
Study NCT05222243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping with calcium hydroxide
Description: Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
Study NCT05222243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct pulp capping with MTA
Description: Capping exposed dental pulps during cavity preparation in primary teeth with MTA
Study NCT05222243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct pulp capping with Formocresol
Description: Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
Study NCT03242070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory-based PP eLearning Program(T-PeP)
Description: Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program.
Study NCT04166227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroscopy
Description: Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
Study NCT04166227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
Study NCT01225536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 736
Description: Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Study NCT00870324 — intervention group
Intervention type: DEVICE
Intervention: OptiSense Lead
Description: The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead.
Study NCT01769222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo local radiation therapy, 10 Gy x 3 fractions
Study NCT03893617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
Study NCT03893617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
Study NCT03893617 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acute stress task
Description: Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
Study NCT03893617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute stress task
Description: Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
Study NCT03893617 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No stress task
Description: Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
Study NCT03893617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No stress task
Description: Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
Study NCT00483145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)
Study NCT00483145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser
Study NCT00483145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
Study NCT00057941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study NCT00057941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00057941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study NCT00057941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00380588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 milligrams per square meter (mg/m2), intravenous (IV)
Study NCT00380588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 25 milligrams per square meter (mg/m2), intravenous (IV)
Study NCT01989884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortataxel
Description: 75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03539926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lit-control®pH Meter
Description: Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
Study NCT03539926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Reactive strips
Description: Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
Study NCT01942616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition 1: Perpetrator Positive
Description: Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
Study NCT01942616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition 2: Perpetrator Negative
Description: The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
Study NCT01942616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Condition 3: Placebo
Description: This intervention provides no details for the participant and is for comparison use in the study.
Study NCT01526135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)
Study NCT01526135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
Study NCT03672240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
Study NCT03401281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50g extra virgin coconut oil daily for four weeks
Study NCT03401281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g butter daily for four weeks
Study NCT03401281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 50g extra virgin olive oil daily for four weeks
Study NCT01742208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
Study NCT01742208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
Study NCT01742208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
Study NCT00818298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprazidone
Description: Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
Study NCT04642781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: reading of a text
Description: Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
Study NCT02169752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.
Study NCT02169752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.
Study NCT00715676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily
Study NCT00715676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001
Description: oral, once daily
Study NCT02667951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home-based caregiver-training program
Description: A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
Study NCT01529554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: (d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
Study NCT01529554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo tablets manufactured to be identical to verum tablets except content of everolimus